



RON CHAPMAN, MD, MPH
Director & State Health Officer

State of California—Health and Human Services Agency
California Department of Public Health



EDMUND G. BROWN JR.
Governor

OFFICE OF AIDS
AIDS Drug Assistance Program (ADAP)

Management Memorandum
Memorandum Number: 2012-08

DATE: September 26, 2012

TO: ADAP COORDINATORS
ADAP ENROLLMENT WORKERS

SUBJECT: ADDITION OF ELVITEGRAVIR 150mg/COBICISTAT
150mg/EMTRICITABINE 200mg/TENOFOVIR DISOPROXIL FUMARATE
300mg TABLETS TO THE ADAP FORMULARY

Effective September 26, 2012, elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg /tenofovir disoproxil fumarate 300mg (Stribild) tablets will be added to the ADAP formulary. The U.S. Food and Drug Administration approved elvitegravir /cobicistat /emtricitabine/tenofovir disoproxil fumarate, a one-pill-per-day, four-drug combination antiretroviral (ARV) drug, for the treatment of HIV-1 infection in adults who are treatment naïve.

Elvitegravir /cobicistat /emtricitabine/tenofovir disoproxil fumarate is a fixed dose ARV combination tablet that is to be taken once a day with food.

ADAP now has 184 drugs on the formulary.

If you have any questions regarding the addition of this medication to the ADAP formulary, please contact me at (916) 449-5943.

Celia Banda-Brown, Chief
ADAP Section
Office of AIDS